J Gynecol Oncol.  2013 Apr;24(2):154-159. 10.3802/jgo.2013.24.2.154.

A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer

• Isonishi S
• Suzuki M
• Nagano H
• Takagi K
• Shimauchi
• Kawabata M
• Ochiai K

• KMID: 2288547
• DOI: http://doi.org/10.3802/jgo.2013.24.2.154

Abstract

OBJECTIVE
To test the concept of taxane sequencing, this feasibility trial evaluated maintenance of docetaxel after paclitaxel and carboplatin combination chemotherapy in patients with stage IC-IV ovarian cancer.
METHODS
All patients received debulking surgery followed by paclitaxel and carboplatin chemotherapy. Attainment of clinically defined complete or partial response was confirmed by image scanning. Maintenance of docetaxel started at an initial dose of 70 mg/m2 every 4 weeks for 6 cycles and was extended to 10 cycles unless disease progression and/or recurrence during the protocol therapy or unacceptable toxicities were seen.
RESULTS
Stage subsets in 20 eligible patients were as follows: IIIB, 2 patients (10%); IIIC, 13 patients (65%); IV, 5 patients (25%). Neutropenia was common (40% with grade 3 or 4) and was most frequent during first or second cycle although the disabling peripheral neuropathy was not observed. Twelve patients completed protocol therapy (6< or =cycles), while 8 patients failed to complete 6-cycle chemotherapy, because of progressive disease (5 patients) or grade 4 toxicities (3 patients). Median PFS was 20 months and 3-year PFS rate was 12%. Median overall survival was 39 months and 3-year OS rate was 69%.
CONCLUSION
Six cycles of single-agent docetaxel maintenance chemotherapy is feasible and generally tolerable to women with advanced ovarian cancer who attained a clinically defined response to initial paclitaxel and carboplatin based chemotherapy.

Keyword

Chemotherapy; Docetaxel; Maintenance; Ovarian cancer

MeSH Terms

Bridged Compounds
Carboplatin
Disease Progression
Drug Therapy, Combination
Feasibility Studies
Female
Humans
Maintenance Chemotherapy
Neutropenia
Ovarian Neoplasms
Paclitaxel
Peripheral Nervous System Diseases
Recurrence
Taxoids
Bridged Compounds
Carboplatin
Paclitaxel
Taxoids

Figure

• 

  Fig. 1 Progression-free survival (PFS) (A) and overall survival (OS) (B) of 20 patients treated with single-agent docetaxel as maintenance therapy. Median PFS was 20 months and 3-year PFS rate was 12%. Median OS was 39 months and 3-year OS was 69%.

Reference

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996. 334:1–6.

2. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000. 92:699–708.

3. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, editors. SEER cancer statistics review, 1975-2009 (Vintage 2009 populations). 2011. cited 2013 Feb 10. Bethesda, MD: National Cancer Institute;Available from: http://seer.cancer.gov/csr/1975_2009_pops09/.

4. Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006. 98:1036–1045.

5. De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol. 2004. 22:2635–2642.

6. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003. 21:2460–2465.

7. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011. 365:2473–2483.

8. Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, et al. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol. 1999. 17:2069–2080.

9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958. 53:457–481.

10. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011. 365:2484–2496.

11. Nakajima K, Isonishi S, Saito M, Tachibana T, Ishikawa H. Characterization of two independent, exposure-time dependent paclitaxel-resistant human ovarian carcinoma cell lines. Hum Cell. 2010. 23:156–163.